Walgreens, Prothena in pact for early-stage Alzheimer’s trial
Apr. 13, 2023 8:57 AM ETWalgreens Boots Alliance, Inc. (WBA), PRTABy: Dulan Lokuwithana, SA News Editor2 Comments
phototechno
- Walgreens (NASDAQ:WBA) and clinical-stage biotech Prothena (NASDAQ:PRTA) have joined hands to accelerate the patient identification and recruitment for the latter’s ongoing early-stage trial for Alzheimer’s candidate PRX012, the companies announced Thursday.
- The Phase 1 study named ASCENT-2 is designed to evaluate the safety and tolerability of the anti-amyloid beta antibody in patients with Alzheimer’s disease.
- Currently, single ascending dose (SAD) and multiple ascending dose (MAD) phases of ASCENT-2 are underway, with topline data expected by the end of the year.
- “At Prothena, we’re excited about PRX012 and the impact it could have as a next-generation Alzheimer’s disease treatment with the potential for more convenient administration for patients and caregivers,” medical chief of Prothena (PRTA), Hideki Garren remarked.
- Walgreens (WBA) cited challenges in patient enrollment in launching its clinical trial business in June 2022.
- According to Seeking Alpha contributor Geoffrey Seiler, the company is aggressively investing in its healthcare segment as it seeks to become an integrated player in the healthcare-pharmacy services business.